BILLERICA, Mass.--(BUSINESS WIRE)--
Bruker Corporation (NASDAQ:BRKR) today announced the appointment of
Anthony (‘Tony’) Mattacchione as Chief Financial Officer, effective
immediately. Mr. Mattacchione has served as the Company’s Interim Chief
Financial Officer since June 2015, and he previously served as Bruker’s
Senior Vice President of Finance & Accounting.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160222005518/en/
Anthony Mattacchione named CFO of Bruker Corporation (Photo: Business Wire)
Frank Laukien, Bruker’s President and CEO, stated: “On behalf of
Bruker’s Board and executive management team, I am very pleased to
congratulate Tony on his appointment. Tony has the strategic and
leadership skills, as well as the operational experience and focus, to
assist Bruker in driving continuous improvements in operational
excellence and financial performance. I am convinced that Tony will be
an excellent Chief Financial Officer for Bruker.”
“Tony has been a key leader of the Bruker finance team since he joined
the Company,” added John Ornell, a Bruker director and member of the
Board’s Audit Committee. “Tony has performed flawlessly in his role as
interim CFO, and he has been a very strong contributor to Bruker in many
aspects. I now look forward to working with Tony as Bruker’s CFO, and to
mentoring Tony using my 13 years of experience as a public-company CFO.”
Mr. Mattacchione brings more than thirty years of financial, accounting,
operational and management experience to Bruker’s CFO position. Prior to
becoming Bruker’s Interim CFO in 2015, he had responsibility for
Bruker’s global finance and accounting functions, including financial
planning & analysis, corporate accounting, public company reporting,
treasury, tax, shared financial services, internal controls and audit,
and global ERP business processes. Mr. Mattacchione has been, and will
continue to be, a key leader in upgrading Bruker’s financial and ERP
systems, and in implementing advanced management processes at Bruker.
Prior to joining Bruker, Mr. Mattacchione served as Chief Financial
Officer of EMD Millipore Corporation, a subsidiary of Merck KGaA, from
2010 to 2013. Previously, he was Vice President, Controller and Chief
Accounting Officer of Millipore Corporation between 2006 and 2010. He
also held various financial leadership roles during a 16-year career at
Gerber Scientific. Mr. Mattacchione is a certified public accountant,
and holds an MBA from the University of Connecticut.
Tony Mattacchione commented: “I am delighted and honored to have been
appointed as Bruker’s CFO. It will be a pleasure to work with our Board,
CEO and executive management team to drive Bruker’s next phase of
Operational Excellence, and to lead our financial strategy of profitable
revenue growth, steady margin expansion, further working capital
improvements, high RoIC, and disciplined capital deployment. I believe
Bruker is well on its way to becoming an even better company - for our
customers, our employees and our shareholders.”
About Bruker Corporation
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve the
quality of human life. Bruker’s high-performance scientific research
instruments and high-value analytical solutions enable scientists to
explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation,
productivity and customer success in life science molecular research, in
applied and pharma applications, and in microscopy, nano-analysis and
industrial applications, as well as in cell biology, preclinical
imaging, clinical research, microbiology and molecular diagnostics. For
more information, please visit: http://www.bruker.com.
Forward Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to risks and uncertainties that could
cause actual results to differ materially from those projected,
including, but not limited to, risks and uncertainties relating to
adverse changes in conditions in the global economy and volatility in
the capital markets, the integration of businesses we have acquired or
may acquire in the future, our ability to successfully implement our
restructuring initiatives, changing technologies, product development
and market acceptance of our products, the cost and pricing of our
products, manufacturing, competition, dependence on collaborative
partners and key suppliers, capital spending and government funding
policies, changes in governmental regulations, realization of
anticipated benefits from economic stimulus programs, intellectual
property rights, litigation, exposure to foreign currency fluctuations
and other risk factors discussed from time to time in our filings with
the Securities and Exchange Commission. These and other factors are
identified and described in more detail in our filings with the SEC,
including, without limitation, our annual report on Form 10-K for the
year ended December 31, 2014 and subsequently filed Quarterly Reports on
Form 10-Q. We expressly disclaim any intent or obligation to update
these forward-looking statements other than as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160222005518/en/
Source: Bruker Corporation